These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 33339292)

  • 41. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
    Collins I; Wang H; Caldwell JJ; Chopra R
    Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
    Moon S; Lee BH
    Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
    VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
    J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
    Pettersson M; Crews CM
    Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent Advances in PROTACs for Drug Targeted Protein Research.
    Yao T; Xiao H; Wang H; Xu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs.
    Gong L; Cui D; Xiong X; Zhao Y
    Adv Exp Med Biol; 2020; 1217():317-347. PubMed ID: 31898236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
    Rothweiler EM; Brennan PE; Huber KVM
    Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expanding PROTACtable genome universe of E3 ligases.
    Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
    Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A small-molecule degron with a phenylpropionic acid scaffold.
    Tomoshige S; Komatsu F; Kikuchi T; Sugiyama M; Kawasaki Y; Ohgane K; Furuyama Y; Sato S; Ishikawa M; Kuramochi K
    Bioorg Med Chem; 2024 Jul; 109():117789. PubMed ID: 38870716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assays and technologies for developing proteolysis targeting chimera degraders.
    Liu X; Zhang X; Lv D; Yuan Y; Zheng G; Zhou D
    Future Med Chem; 2020 Jun; 12(12):1155-1179. PubMed ID: 32431173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted Protein Degradation through E2 Recruitment.
    Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
    ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.